Study of Trikafta on Gut-Lung Connection in CF
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study is looking at how a new combination medicine (Trikafta) affects the lungs and gut in people with cystic fibrosis who carry the DeltaF508 mutation. It aims to understand how the medicine works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cystic fibrosis, confirmed by a high sweat chloride level.
- You carry at least one DeltaF508 gene mutation.
- You are about to start taking the combination drug elexacaftor/tezacaftor/ivacaftor (Trikafta) as part of your usual care.
- You have not taken any other CFTR modulator medicine before.
- You are not pregnant or under legal guardianship/curatorship.
- You agree to be followed through the French cystic fibrosis registry.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how starting Trikafta affects exercise ability and breathing in adults with cystic fibrosis. You may be asked to do supervised breathing and exercise tests to see if Trikafta helps your lung function and stamina.
This observational study follows people with cystic fibrosis (CF) to understand the long-term impact of CFTR modulator medicines. It may help researchers see how these treatments work over time in real life.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study uses MRI scans to monitor lung health in teens and young adults with cystic fibrosis who are taking Trikafta. It aims to find better ways to track how the disease affects the lungs over time.
This trial tests a new drug called SPL84 for people with cystic fibrosis who have a specific gene mutation (3849+10kb C->T). It aims to see if the drug is safe and can improve lung function. The study has two paths: one for people not taking certain CF drugs, and one for those who are already on Trikafta or Alyftrek.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.